Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris
Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million